Frank Lee, Forma Therapeutics CEO (MassBio)
Right as it gets a date with FDA, Forma offloads IDH1 inhibitor to Rigel
An IDH1 inhibitor on the cusp of an FDA decision is changing hands.
Watertown, MA-based Forma Therapeutics has long made it clear that olutasidenib, its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
